Analysts' Actions: FB, ONXX, RHT, UA, V

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

AO Smith ( AOS) rated new Market Perform at BMO. $55 price target. Company is seeing slower domestic growth.

Brookfield Infrastructure Partners ( BIP) rated new Neutral at Citigroup. $34 price target. Fully valued at current levels despite risk averse business model.

Centerpoint ( CNP) downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $21 price target.

CIFC ( DFR) downgraded to sell at TheStreet Ratings.

Facebook ( FB) rated new Hold at Argus. Still uncertain how the company will monetize growth in mobile access.

Intercontinental Exchange ( ICE) rated new Hold at BGB Securities. $145 price target. Lower commodity prices and volatility could weigh on volumes.

Laboratory Corp. of America ( LH) rated new Buy at Canaccord. $100 price target. Company is a low-cost provider and volumes have likely troughed.

NII ( NIHD) downgraded at Wells to Market Perform, Wells Fargo said. Estimates also cut, as the dollar remains an earnings headwind.

New Mountain Finance ( NMFC) initiated as hold at TheStreet Ratings.

Onyx Pharmaceuticals ( ONXX) rated new Buy at Deutsche. $58 price target. Kyprolis should be the company's next main growth driver.

Onyx Pharmaceuticals upgraded at Brean Murray from Hold to Buy. $60 price target. New cancer drug should be approved by the FDA next month.

TJX Companies ( TJX) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company is likely gaining market share from JCP, which could help boost sales growth.

Under Armour ( UA) downgraded at UBS to Neutral from Buy, UBS said. $105 price target. Stock run, high valuation, diminishing outperformance.

Woodward ( WWD) rated new Outperform at Credit Suisse. $48 price target. Company has strong market positioning and can deliver consistent organic growth.

Wright Express ( WXS) downgraded at Citigroup to Sell from Neutral, Citigroup said. $56 price target. Near term pressures from declining fuel prices.

STOCK COMMENTS / EPS CHANGES

Accenture ( ACN) estimates, target cut at BMO. Shares of ACN now seen reaching $66, according to BMO Capital. Estimates also reduced, given currency headwinds. Market Perform rating.

Bed, Bath & Beyond ( BBBY) estimates cut at Credit Suisse through 2014, Credit Suisse said. Comp sales have slowed down. Outperform rating and $91 price target.

Bed Bath & Beyond numbers lowered at Oppenheimer. Shares of BBBY now seen reaching $80, Oppenheimer said. Estimates also lowered on earnings release. Outperform rating.

Dollar General ( DG) numbers upped at BofA/Merrill. DG estimates were boosted through 2013, Bank of America/Merrill Lynch said. Company should continue to show solid comp sales momentum. Buy rating and new $60 price target.

Equinix ( EQIX) numbers raised at Jefferies. Shares of EQIX now seen reaching $200, Jefferies said. Estimates also raised on market expansion. Buy rating.

Mastercard ( MA) estimates, target increased at Morgan Stanley. MA estimates were raised through 2014, Morgan Stanley said. Company has multiple potential growth drivers. Overweight rating and new $535 price target.

Micron ( MU) estimates, target cut at Sterne Agee. Shares of MU now seen reaching $10, according to Sterne Agee. Estimates also reduced, given lower pricing and retail demand. Buy rating.

Onyx Pharmaceuticals ( ONXX) numbers raised at Goldman. Shares of ONXX now seen reaching $63, according to Goldman Sachs. Estimates also increased, given expected FDA approval for the company's new blood cancer treatment. Buy rating.

Onyx Pharmaceuticals numbers raised at Jefferies. Shares of ONXX now seen reaching $55, Jefferies said. Estimates also raised on Carfilzomib likely being approved. Hold rating.

Procter & Gamble ( PG) estimates lowered at Credit Suisse through 2014, Credit Suisse said. Company is seeing slower market growth and losing share. Outperform rating and $70 price target.

Red Hat ( RHT) numbers reduced at BMO. RHT estimates were cut through 2014, BMO Capital said. Billings growth has been disappointing. Outperform rating and new $60 price target.

Red Hat target lowered at Citigroup to $66. Lower terminal multiple. Buy rating.

Visa ( V) estimates, target boosted at Goldman. Shares of V now seen reaching $147, according to Goldman Sachs. Estimates also upped, given better industry fundamentals. Overweight rating.

Zumiez ( ZUMZ) estimates, target raised at Credit Suisse. Shares of ZUMZ now seen reaching $41, according to Credit Suisse. Estimates also increased, as a recent acquisition in Europe should be accretive. Neutral rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain